Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Whole-genome sequencing as an improved means of investigating Neisseria gonorrhoeae treatment failures.

Buckley C, Beatson SA, Limnios A, Lahra MM, Whiley DM, Forde BM.

Sex Health. 2019 Sep 4. doi: 10.1071/SH19012. [Epub ahead of print]

PMID:
31481151
2.

World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts.

Unemo M, Lahra MM, Cole M, Galarza P, Ndowa F, Martin I, Dillon JR, Ramon-Pardo P, Bolan G, Wi T.

Sex Health. 2019 Aug 23. doi: 10.1071/SH19023. [Epub ahead of print]

PMID:
31437420
3.

Australian Gonococcal Surveillance Programme, 1 January to 31 March 2018

Lahra MM, Enriquez RP.

Commun Dis Intell (2018). 2019 Jun 17;43. doi: 10.33321/cdi.2019.43.27. No abstract available.

4.

Microbial Keratitis and Ocular Surface Disease: A 5-Year Study of the Microbiology, Risk Factors and Clinical Outcomes in Sydney, Australia.

Khoo P, Cabrera-Aguas M, Robaei D, Lahra MM, Watson S.

Curr Eye Res. 2019 Jun 24:1-8. doi: 10.1080/02713683.2019.1631852. [Epub ahead of print]

PMID:
31189397
5.

Emergence and spread of ciprofloxacin-resistant Neisseria gonorrhoeae in New South Wales, Australia: lessons from history.

Hanrahan JK, Hogan TR, Buckley C, Trembizki E, Mitchell H, Lau CL, Whiley DM, Lahra MM.

J Antimicrob Chemother. 2019 Aug 1;74(8):2214-2219. doi: 10.1093/jac/dkz182.

PMID:
31170281
6.

Australian Gonococcal Surveillance Programme, 1 July to 30 September 2018

Lahra MM, Enriquez RP, George CRR; The National Neisseria Network.

Commun Dis Intell (2018). 2019 May 15;43. doi: 10.33321/cdi.2019.43.19. No abstract available.

7.

Australian Gonococcal Surveillance Programme Annual Report, 2017

Lahra MM, Enriquez R, George CRR.

Commun Dis Intell (2018). 2019 Apr 15;43. doi: 10.33321/cdi.2019.43.13.

8.

Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016.

George CRR, Enriquez RP, Gatus BJ, Whiley DM, Lo YR, Ishikawa N, Wi T, Lahra MM.

PLoS One. 2019 Apr 3;14(4):e0213312. doi: 10.1371/journal.pone.0213312. eCollection 2019.

9.

Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018.

Jennison AV, Whiley D, Lahra MM, Graham RM, Cole MJ, Hughes G, Fifer H, Andersson M, Edwards A, Eyre D.

Euro Surveill. 2019 Feb;24(8). doi: 10.2807/1560-7917.ES.2019.24.8.1900118.

10.

Australian Gonococcal Surveillance Programme Annual Report, 2016.

Lahra MM, Enriquez R.

Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00013-1. Epub 2018 Nov 16.

11.

Treatment for pharyngeal gonorrhoea under threat.

Regan DG, Hui BB, Wood JG, Fifer H, Lahra MM, Whiley DM.

Lancet Infect Dis. 2018 Nov;18(11):1175-1177. doi: 10.1016/S1473-3099(18)30610-8. Epub 2018 Oct 24. No abstract available.

PMID:
30507396
12.

Keratitis antimicrobial resistance surveillance program, Sydney, Australia: 2016 Annual Report.

Watson S, Cabrera-Aguas M, Khoo P, Pratama R, Gatus BJ, Gulholm T, El-Nasser J, Lahra MM.

Clin Exp Ophthalmol. 2019 Jan;47(1):20-25. doi: 10.1111/ceo.13364. Epub 2018 Aug 14.

PMID:
30047184
13.

Direct Detection of penA Gene Associated with Ceftriaxone-Resistant Neisseria gonorrhoeae FC428 Strain by Using PCR.

Whiley DM, Mhango L, Jennison AV, Nimmo G, Lahra MM.

Emerg Infect Dis. 2018 Aug;24(8):1573-1575. doi: 10.3201/eid2408.180295.

14.

Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin.

Whiley DM, Jennison A, Pearson J, Lahra MM.

Lancet Infect Dis. 2018 Jul;18(7):717-718. doi: 10.1016/S1473-3099(18)30340-2. No abstract available.

PMID:
29976521
15.

Australian Meningococcal Surveillance Programme annual report, 2016.

Lahra MM, Enriquez R.

Commun Dis Intell Q Rep. 2017 Dec 1;41(4):E369-E382.

16.

Australian Meningococcal Surveillance Programme, 1 April to 30 June 2017.

Lahra MM, Enriquez R.

Commun Dis Intell Q Rep. 2017 Sep 1;41(3):E241-E242.

17.

Cooperative Recognition of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain.

Lahra MM, Martin I, Demczuk W, Jennison AV, Lee KI, Nakayama SI, Lefebvre B, Longtin J, Ward A, Mulvey MR, Wi T, Ohnishi M, Whiley D.

Emerg Infect Dis. 2018 Apr;24(4). doi: 10.3201/eid2404.171873.

18.

Azithromycin-resistant Neisseria gonorrhoeae spreading amongst men who have sex with men (MSM) and heterosexuals in New South Wales, Australia, 2017.

Whiley DM, Kundu RL, Jennison AV, Buckley C, Limnios A, Hogan T, Enriquez R, El Nasser J, George CR, Lahra MM.

J Antimicrob Chemother. 2018 May 1;73(5):1242-1246. doi: 10.1093/jac/dky017.

PMID:
29373697
19.

Use of whole genome sequencing to investigate an increase in Neisseria gonorrhoeae infection among women in urban areas of Australia.

Buckley C, Forde BM, Trembizki E, Lahra MM, Beatson SA, Whiley DM.

Sci Rep. 2018 Jan 24;8(1):1503. doi: 10.1038/s41598-018-20015-x.

20.

Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.

Archer BN, Chiu CK, Jayasinghe SH, Richmond PC, McVernon J, Lahra MM, Andrews RM, McIntyre PB; Australian Technical Advisory Group on Immunisation (ATAGI) Meningococcal Working Party.

Med J Aust. 2017 Nov 6;207(9):382-387.

PMID:
29092704
21.

Australian Meningococcal Surveillance Programme, 1 January to 31 March 2017.

Lahra MM; for the National Neisseria Network, Australia.

Commun Dis Intell Q Rep. 2017 Jun 30;41(2):E201. No abstract available.

22.

Molecular Antimicrobial Resistance Surveillance for Neisseria gonorrhoeae, Northern Territory, Australia.

Whiley DM, Trembizki E, Buckley C, Freeman K, Baird RW, Beaman M, Chen M, Donovan B, Kundu RL, Fairley CK, Guy R, Hogan T, Kaldor JM, Karimi M, Limnios A, Regan DG, Ryder N, Su JY, Ward J, Lahra MM.

Emerg Infect Dis. 2017 Sep;23(9):1478-1485. doi: 10.3201/eid2309.170427.

23.

Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines.

Alirol E, Wi TE, Bala M, Bazzo ML, Chen XS, Deal C, Dillon JR, Kularatne R, Heim J, Hooft van Huijsduijnen R, Hook EW, Lahra MM, Lewis DA, Ndowa F, Shafer WM, Tayler L, Workowski K, Unemo M, Balasegaram M.

PLoS Med. 2017 Jul 26;14(7):e1002366. doi: 10.1371/journal.pmed.1002366. eCollection 2017 Jul.

24.

Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action.

Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M.

PLoS Med. 2017 Jul 7;14(7):e1002344. doi: 10.1371/journal.pmed.1002344. eCollection 2017 Jul.

25.

Australian Gonococcal Surveillance Programme, 1 July to 30 September 2016
.

Lahra MM, Enriquez RP; Prince of Wales Hospital, Randwick, for The National Neisseria Network.

Commun Dis Intell Q Rep. 2017 Mar 31;41(1):E109-E110. No abstract available.

26.

Australian Gonococcal Surveillance Programme annual report, 2015.

Lahra MM, Enriquez RP; National Neisseria Network.

Commun Dis Intell Q Rep. 2017 Mar 31;41(1):E.

27.

Australian Meningococcal Surveillance Programme, 1 January to 31 March 2016.

Lahra MM, Enriquez RP; Australian Meningococcal Surveillance Programme.

Commun Dis Intell Q Rep. 2016 Sep 30;40(3):E447. No abstract available.

PMID:
28278420
28.

Australian Meningococcal Surveillance Programme, 1 January to 31 March 2016.

Lahra MM, Enriquez RP; Australian Meningococcal Surveillance Programme.

Commun Dis Intell Q Rep. 2016 Sep 30;40(3):E446. No abstract available.

PMID:
28278419
29.

Treatment guidelines after an outbreak of azithromycin-resistant Neisseria gonorrhoeae in South Australia.

Lahra MM, Ward A, Trembizki E, Hermanson J, Clements E, Lawrence A, Whiley D.

Lancet Infect Dis. 2017 Feb;17(2):133-134. doi: 10.1016/S1473-3099(17)30007-5. No abstract available.

PMID:
28134103
30.

Australian Meningococcal Surveillance Programme, 1 July to 30 September 2016.

Lahra MM, Enriquez RP.

Commun Dis Intell Q Rep. 2016 Dec 24;40(4):E560. No abstract available.

31.

Australian Gonococcal Surveillance Programme, 1 April to 30 June 2016.

Lahra MM, Enriquez RP.

Commun Dis Intell Q Rep. 2016 Dec 24;40(4):E557-E559. No abstract available.

32.

Australian Gonococcal Surveillance Programme, 1 January to 31 March 2016.

Lahra MM, Enriquez RP.

Commun Dis Intell Q Rep. 2016 Dec 24;40(4):E554-E556. No abstract available.

33.

Australian Meningococcal Surveillance Programme annual report, 2015.

Lahra MM, Enriquez RP; National Neisseria Network.

Commun Dis Intell Q Rep. 2016 Dec 24;40(4):E503-E511.

34.

Rise in invasive serogroup W meningococcal disease in Australia 2013-2015.

Martin NV, Ong KS, Howden BP, Lahra MM, Lambert SB, Beard FH, Dowse GK, Saul N; Communicable Diseases Network Australia MenW Working Group .

Commun Dis Intell Q Rep. 2016 Dec 24;40(4):E454-E459.

35.

Changes in the rates of Neisseria gonorrhoeae antimicrobial resistance are primarily driven by dynamic fluctuations in common gonococcal genotypes.

Lahra MM, Trembizki E, Buckley C, Donovan B, Chen M, Guy R, Kundu RL, Regan DG, Whiley DM; GRAND Study Investigators.

J Antimicrob Chemother. 2017 Mar 1;72(3):705-711. doi: 10.1093/jac/dkw452.

PMID:
27999043
36.

Epidemiology of Late and Very Late Onset Group B Streptococcal Disease: Fifteen-Year Experience From Two Australian Tertiary Pediatric Facilities.

Bartlett AW, Smith B, George CR, McMullan B, Kesson A, Lahra MM, Palasanthiran P.

Pediatr Infect Dis J. 2017 Jan;36(1):20-24.

PMID:
27749655
37.

Mixed gonococcal infections in a high-risk population, Sydney, Australia 2015: implications for antimicrobial resistance surveillance?

Goire N, Kundu R, Trembizki E, Buckley C, Hogan TR, Lewis DA, Branley JM, Whiley DM, Lahra MM.

J Antimicrob Chemother. 2017 Feb;72(2):407-409. doi: 10.1093/jac/dkw406. Epub 2016 Oct 5.

PMID:
27707989
38.

Further evidence to support the individualised treatment of gonorrhoea with ciprofloxacin.

Trembizki E, Guy R, Donovan B, Kaldor JM, Lahra MM, Whiley DM; GRAND study investigators.

Lancet Infect Dis. 2016 Sep;16(9):1005-1006. doi: 10.1016/S1473-3099(16)30271-7. No abstract available.

PMID:
27684341
39.

The Molecular Epidemiology and Antimicrobial Resistance of Neisseria gonorrhoeae in Australia: A Nationwide Cross-Sectional Study, 2012.

Trembizki E, Wand H, Donovan B, Chen M, Fairley CK, Freeman K, Guy R, Kaldor JM, Lahra MM, Lawrence A, Lau C, Pearson J, Regan DG, Ryder N, Smith H, Stevens K, Su JY, Ward J, Whiley DM.

Clin Infect Dis. 2016 Dec 15;63(12):1591-1598. Epub 2016 Sep 28.

PMID:
27682063
40.

Australian Meningococcal Surveillance Programme annual report, 2014.

Lahra MM, Enriquez RP.

Commun Dis Intell Q Rep. 2016 Jun 30;40(2):E221-8.

41.

Real-time PCR detection of Neisseria gonorrhoeae susceptibility to penicillin.

Buckley C, Trembizki E, Donovan B, Chen M, Freeman K, Guy R, Lahra MM, Kundu RL, Regan DG, Smith HV, Whiley DM; Gonorrhoea Resistance Assessment by Nucleic Acid Detection (GRAND) Study Investigators.

J Antimicrob Chemother. 2016 Nov;71(11):3090-3095. Epub 2016 Jul 25.

PMID:
27494921
42.

The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization.

Unemo M, Golparian D, Sánchez-Busó L, Grad Y, Jacobsson S, Ohnishi M, Lahra MM, Limnios A, Sikora AE, Wi T, Harris SR.

J Antimicrob Chemother. 2016 Nov;71(11):3096-3108. Epub 2016 Jul 17.

43.

Complete Genome Sequences of 11 Haemophilus ducreyi Isolates from Children with Cutaneous Lesions in Vanuatu and Ghana.

Pillay A, Katz SS, Abrams AJ, Ballard RC, Simpson SV, Taleo F, Lahra MM, Batra D, Rowe L, Trees DL, Asiedu K, Chen CY.

Genome Announc. 2016 Jul 7;4(4). pii: e00459-16. doi: 10.1128/genomeA.00459-16.

44.

A comparison of agar dilution with the Calibrated Dichotomous Sensitivity (CDS) and Etest methods for determining the minimum inhibitory concentration of ceftriaxone against Neisseria gonorrhoeae.

Enriquez RP, Goire N, Kundu R, Gatus BJ, Lahra MM.

Diagn Microbiol Infect Dis. 2016 Sep;86(1):40-3. doi: 10.1016/j.diagmicrobio.2016.04.016. Epub 2016 Apr 28.

PMID:
27342784
45.

Australian Gonococcal Surveillance Programme, 1 July to 30 September 2015.

Lahra MM, Enriquez RP; National Neisseria Network.

Commun Dis Intell Q Rep. 2016 Mar 31;40(1):E179-81. No abstract available.

46.

Australian Meningococcal Surveillance Programme, 1 July to 30 September 2015.

Lahra MM, Enriquez RP; Australian Meningococcal Surveillance Programme.

Commun Dis Intell Q Rep. 2015 Dec 31;39(4):E631. No abstract available.

47.

Australian Gonococcal Surveillance Programme, 1 April to 30 June 2015.

Lahra MM, Enriquez RP; National Neisseria Network.

Commun Dis Intell Q Rep. 2015 Dec 31;39(4):E628-30. No abstract available.

48.

Australian Meningococcal Surveillance Programme quarterly report, 1 April to 30 June 2015.

Lahra MM, Kundu R.

Commun Dis Intell Q Rep. 2015 Sep 30;39(3):E495. No abstract available.

49.

Australian Gonococcal Surveillance Programme annual report, 2014.

Lahra MM; Australian Gonococcal Surveillance Programme.

Commun Dis Intell Q Rep. 2015 Sep 30;39(3):E347-54.

50.

A real-time PCR assay for direct characterization of the Neisseria gonorrhoeae GyrA 91 locus associated with ciprofloxacin susceptibility.

Buckley C, Trembizki E, Donovan B, Chen M, Freeman K, Guy R, Kundu R, Lahra MM, Regan DG, Smith H, Whiley DM; GRAND Study Investigators.

J Antimicrob Chemother. 2016 Feb;71(2):353-6. doi: 10.1093/jac/dkv366. Epub 2015 Nov 3.

PMID:
26538505

Supplemental Content

Loading ...
Support Center